NVS250117C125000
- 0.05
- 0.000.00%
Novartis AG Newsroom
LVMH Is Once Again the Largest Company in Europe by Market Cap
Jefferies Remains a Hold on Novartis AG (NOVN)
Novartis Obtains Temporary Court Order Blocking Generic Version of Entresto
Legal Uncertainties and Patent Risks Lead to Hold Rating for Novartis AG
Express News | U.S. FDA Chief Califf Says Current Regulations Not Enough To Protect Americans From Risks Of Compounded GLP-1 Drugs
Novartis AG Flat Thursday, Underperforms Market
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Express News | 'As Bird Flu Affects More People And Animals, CDC Urges Faster Testing' - Washington Post
Novartis Wins Temporary Stay on Heart Failure Drug's Generic Version in US
Top Gap Ups and Downs on Wednesday: IONQ, BCS, GS and More
Swiss Buybacks Likely to Increase After Dip in 2024 -- Market Talk
Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Revised)
Dividend Aristocrats Can't Handle Rising Rates. These Are Better Income Bets.
Schrödinger Receives Regulatory Approval for Novartis Collaboration
Illumina Launches Proteomics Pilot With 50,000 UK Biobank Samples, Partners With GSK, J&J, and Novartis
Novartis: There Are Currently No Generic Versions of Entresto Available in the U.S.
Novartis to Work to Enforce Patent Through Pediatric Exclusivity Period Expiring in July 2025
Novartis: U.S. Court of Appeals Affirms Validity of Entresto Combination Patent
Novartis AG: Hold Rating Maintained Amid Legal Uncertainties and Limited Growth Prospects